<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00280709</url>
  </required_header>
  <id_info>
    <org_study_id>ELLA</org_study_id>
    <nct_id>NCT00280709</nct_id>
  </id_info>
  <brief_title>Biliary Metal Stent Study: Metal Stents for Management of Distal Malignant Biliary Obstruction</brief_title>
  <official_title>Covered Versus Uncovered Metal Stents for Management of Distal Malignant Biliary Obstruction? Results of a Randomized Prospective Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Linkoeping</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Linkoeping</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose is to compare patency of two different types of biliary metal stents,
      i.e. covered versus uncovered Nitinella metal stent. Secondary purposes are to determine
      frequency of complications in the two groups, e.g. cholecystitis, pancreatitis, and
      cholangitis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical follow-up every month, starting one month after stent insertion. Clinical and/or laboratory signs of stent dysfunction?</measure>
    <time_frame>12 months after stent insertion</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">400</enrollment>
  <condition>Bile Duct Obstruction</condition>
  <condition>Pancreatic Cancer</condition>
  <condition>Gallbladder Cancer</condition>
  <condition>Bile Duct Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Covered metal stent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Uncovered metal stent</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>&quot;Nitinella&quot; ; SX-ELLA Stent Biliary (biliary metal stent)</intervention_name>
    <description>Nitinella covered (arm 1) or uncovered (arm 2) biliary metal stent. Maximum diameter 10 mm, length 52 or 72 mm</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  20 years of age or older

          -  oral and written information given and informed consent obtained

          -  clinical data in accordance with malignant bile duct obstruction

          -  ultrasonography signs of extrahepatic malignant common bile duct obstruction

          -  typical radiological findings at ERCP of malignant common bile duct stenosis

          -  proximal margin of the bile duct stenosis at least 2 cm from the hepatic confluence

          -  bilirubin &gt; 50 micromol/L

          -  radical surgery estimated not possible (temporary stenting with insertion of a plastic
             stent can be obtained but should be replaced by a metal stent within 4 weeks after the
             first ERCP procedure, and the patient is randomized at the time of insertion of the
             metal stent)

        Exclusion Criteria:

          -  patients with active hepatitis or other hepatic diseases that may cause jaundice

          -  informed consent not obtained

          -  metastasis with numerous significant intrahepatic stenosis causing blockage of one or
             more segments of the liver (if no segment blockage, liver metastasis is not an
             exclusion criteria)

          -  the patient is probably a candidate for surgical resection

          -  suspicion of a non-malignant bile duct obstruction, e.g. stones or benign stenosis
             (should initiate further investigations)

          -  the proximal end of the stenosis is located within 2 cm from the hepatic confluence

          -  the patient has previously undergone BII or Roux-en-Y gastric resection, or has a
             significant duodenal obstruction making ERCP difficult

          -  previously (more than 4 weeks earlier) treated with a bile duct stent

          -  severe coagulation disturbance (PK-INR &gt; 1.6)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric P Kullman, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Surgery, University Hostpital, Linkoping, Sweden.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Claes Soderlund, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Surgery, Sodersjukhuset, Stockholm, Sweden.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bo Ohlin, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Surgery, Central Hospital of Blekinge, Karlskrona, Sweden.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ervin Toth, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Endoscopy, University Hospital MAS, Malm√∂, Sweden.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carl-Eric Leijonmarck, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Surgery, S:t Goran Hospital, Stockholm, Sweden.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eduard Jonas, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Surgery, Danderyd Hospital, Stockholm, Sweden.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Claes Rudberg, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Surgery, Central Hospital, Vasteras, Sweden.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kalev Teder, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Surgery, Central Hospital, Norrkoping, Sweden.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Erik Svartholm, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Surgery, Ryhov Hospital, Jonkoping, Sweden.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mehmet Gozen, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Surgery, Vastervik Hospital, Vastervik, Sweden.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Surgery, University Hospital</name>
      <address>
        <city>Linkoping</city>
        <zip>58185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>December 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 20, 2006</study_first_submitted>
  <study_first_submitted_qc>January 20, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2006</study_first_posted>
  <last_update_submitted>August 9, 2011</last_update_submitted>
  <last_update_submitted_qc>August 9, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 10, 2011</last_update_posted>
  <responsible_party>
    <name_title>Eric Kullman, M.D., Associate Professor</name_title>
    <organization>Department of Surgery, University Hospital, Linkoping, Sweden</organization>
  </responsible_party>
  <keyword>Bile duct</keyword>
  <keyword>Bile duct obstruction</keyword>
  <keyword>Biliary stent</keyword>
  <keyword>Metal stent</keyword>
  <keyword>ERCP</keyword>
  <keyword>Patency</keyword>
  <keyword>Complication</keyword>
  <keyword>Stent occlusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Gallbladder Neoplasms</mesh_term>
    <mesh_term>Bile Duct Neoplasms</mesh_term>
    <mesh_term>Cholangiocarcinoma</mesh_term>
    <mesh_term>Cholestasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

